Porphyrias

The Lancet

Volumn 375, Issue 9718, 2010, Pages 924-937

  Puy, Hervé ^a,b   Gouya, Laurent ^a,b,c   Deybach, Jean Charles ^a,b  

^a HÔPITAL LOUIS MOURIER   (France)

^b CENTRE DE RECHERCHE BIOMÉDICALE BICHAT BEAUJON CRB3   (France)

^c LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORPROMAZINE; CLONAZEPAM; CYCLIZINE; DIAZEPAM; DIHYDROCODEINE; GABAPENTIN; HEME; LACTULOSE; LAXATIVE; LORAZEPAM; MAGNESIUM SULFATE; ONDANSETRON; OPIATE; PARACETAMOL; PROMAZINE; PROTOPORPHYRIN; SENNA EXTRACT;

ABDOMINAL PAIN; ACUTE INTERMITTENT PORPHYRIA; ANXIETY DISORDER; BACKACHE; BLISTER; CLINICAL ASSESSMENT; CONFUSION; CONGENITAL ERYTHROPOIETIC PORPHYRIA; CONSTIPATION; CONVULSION; ENZYME DEFICIENCY; GENE MUTATION; HALLUCINATION; HEART ARRHYTHMIA; HEMOLYSIS; HEPATOERYTHROPOIETIC PORPHYRIA; HUMAN; HYPERTENSION; INSOMNIA; LIMB PAIN; METABOLIC DISORDER; NAUSEA; NEUROLOGIC DISEASE; PALLIATIVE THERAPY; PATHOGENESIS; PATIENT COUNSELING; PHOTOSENSITIVITY; PORPHYRIA; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SKIN DEFECT; SKIN FRAGILITY; SKIN MANIFESTATION; TACHYCARDIA; VOMITING;

EID: 77749251871     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(09)61925-5     Document Type: Review

References (140)

1. Anderson K.E., Sassa S.S., Bishop D.F., and Desnick R.J. Disorders of heme biosynthesis: X-linked sideroblastic anemia and the porphyrias. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The metabolic basis of inherited disease. 8th edn. (2001), McGraw-Hill, New York
2. Moore M.R., McColl K.M., Rimington C., and Goldberg A. Disorders of porphyrin metabolism (1987), Plenum Publishing Corporation, New York
3. Bishop D.F., Henderson A.S., and Astrin K.H. Human delta-aminolevulinate synthase: assignment of the housekeeping gene to 3p21 and the erythroid-specific gene to the X chromosome. Genomics 7 (1990) 207-214
4. Fraser D.J., Podvinec M., Kaufmann M.R., and Meyer U.A. Drugs mediate the transcriptional activation of the 5-aminolevulinic acid synthase (ALAS1) gene via the chicken xenobiotic-sensing nuclear receptor (CXR). J Biol Chem 277 (2002) 34717-34726
5. Thunell S. (Far) Outside the box: genomic approach to acute porphyria. Physiol Res 55 suppl 2 (2006) 43-66
6. Smith S.J., and Cox T.M. Translational control of erythroid delta-aminolevulinate synthase in immature human erythroid cells by heme. Cell Mol Biol (Noisy-le-grand) 43 (1997) 103-114
7. Schneider-Yin X., Hergersberg M., Goldgar D.E., et al. Ancestral founder of mutation W283X in the porphobilinogen deaminase gene among acute intermittent porphyria patients. Hum Hered 54 (2002) 69-81
8. Floderus Y., Shoolingin-Jordan P.M., and Harper P. Acute intermittent porphyria in Sweden. Molecular, functional and clinical consequences of some new mutations found in the porphobilinogen deaminase gene. Clin Genet 62 (2002) 288-297
9. Meissner P.N., Dailey T.A., Hift R.J., et al. A R59W mutation in human protoporphyrinogen oxidase results in decreased enzyme activity and is prevalent in South Africans with variegate porphyria. Nat Genet 13 (1996) 95-97
10. Bylesjo I., Wikberg A., and Andersson C. Clinical aspects of acute intermittent porphyria in northern Sweden: a population-based study. Scand J Clin Lab Invest 69 (2009) 612-618
11. Andersson C., Innala E., and Backstrom T. Acute intermittent porphyria in women: clinical expression, use and experience of exogenous sex hormones. A population-based study in northern Sweden. J Intern Med 254 (2003) 176-183
12. Mustajoki P., and Nordmann Y. Early administration of heme arginate for acute porphyric attacks. Arch Intern Med 153 (1993) 2004-2008
13. Crimlisk H.L. The little imitator-porphyria: a neuropsychiatric disorder. J Neurol Neurosurg Psychiatry 62 (1997) 319-328
14. Hift R.J., and Meissner P.N. An analysis of 112 acute porphyric attacks in Cape Town, South Africa: evidence that acute intermittent porphyria and variegate porphyria differ in susceptibility and severity. Medicine (Baltimore) 84 (2005) 48-60
15. Kauppinen R., and von und zu Fraunberg M. Molecular and biochemical studies of acute intermittent porphyria in 196 patients and their families. Clin Chem 48 (2002) 1891-1900
16. Lim C.K., and Peters T.J. Urine and faecal porphyrin profiles by reversed-phase high-performance liquid chromatography in the porphyrias. Clin Chim Acta 139 (1984) 55-63
17. Aarsand A.K., Petersen P.H., and Sandberg S. Estimation and application of biological variation of urinary delta-aminolevulinic acid and porphobilinogen in healthy individuals and in patients with acute intermittent porphyria. Clin Chem 52 (2006) 650-656
18. Hift R.J., Davidson B.P., van der Hooft C., Meissner D.M., and Meissner P.N. Plasma fluorescence scanning and fecal porphyrin analysis for the diagnosis of variegate porphyria: precise determination of sensitivity and specificity with detection of protoporphyrinogen oxidase mutations as a reference standard. Clin Chem 50 (2004) 915-923
19. Da Silva V., Simonin S., Deybach J.C., Puy H., and Nordmann Y. Variegate porphyria: diagnostic value of fluorometric scanning of plasma porphyrins. Clin Chim Acta 238 (1995) 163-168
20. Kuhnel A., Gross U., and Doss M.O. Hereditary coproporphyria in Germany: clinical-biochemical studies in 53 patients. Clin Biochem 33 (2000) 465-473
21. Hindmarsh J.T., Oliveras L., and Greenway D.C. Biochemical differentiation of the porphyrias. Clin Biochem 32 (1999) 609-619
22. Allen K.R., Whatley S.D., Degg T.J., and Barth J.H. Hereditary coproporphyria: comparison of molecular and biochemical investigations in a large family. J Inherit Metab Dis 28 (2005) 779-785
23. Puy H., Deybach J.C., Lamoril J., et al. Molecular epidemiology and diagnosis of PBG deaminase gene defects in acute intermittent porphyria. Am J Hum Genet 60 (1997) 1373-1383
24. Rosipal R., Lamoril J., Puy H., et al. Systematic analysis of coproporphyrinogen oxidase gene defects in hereditary coproporphyria and mutation update. Hum Mutat 13 (1999) 44-53
25. Whatley S.D., Puy H., Morgan R.R., et al. Variegate porphyria in Western Europe: identification of PPOX gene mutations in 104 families, extent of allelic heterogeneity, and absence of correlation between phenotype and type of mutation. Am J Hum Genet 65 (1999) 984-994
26. Lamoril J., Puy H., Whatley S.D., et al. Characterization of mutations in the CPO gene in British patients demonstrates absence of genotype-phenotype correlation and identifies relationship between hereditary coproporphyria and harderoporphyria. Am J Hum Genet 68 (2001) 1130-1138
27. Grandchamp B., Picat C., Kauppinen R., et al. Molecular analysis of acute intermittent porphyria in a Finnish family with normal erythrocyte porphobilinogen deaminase. Eur J Clin Invest 19 (1989) 415-418
28. Whatley S.D., Mason N.G., Woolf J.R., Newcombe R.G., Elder G.H., and Badminton M.N. Diagnostic strategies for autosomal dominant acute porphyrias: retrospective analysis of 467 unrelated patients referred for mutational analysis of the HMBS, CPOX, or PPOX gene. Clin Chem 55 (2009) 1406-1414
29. Meyer U.A., Schuurmans M.M., and Lindberg R.L. Acute porphyrias: pathogenesis of neurological manifestations. Semin Liver Dis 18 (1998) 43-52
30. Sima A.A., Kennedy J.C., Blakeslee D., and Robertson D.M. Experimental porphyric neuropathy: a preliminary report. Can J Neurol Sci 8 (1981) 105-113
31. Soonawalla Z.F., Orug T., Badminton M.N., et al. Liver transplantation as a cure for acute intermittent porphyria. Lancet 363 (2004) 705-706
32. Podvinec M., Handschin C., Looser R., and Meyer U.A. Identification of the xenosensors regulating human 5-aminolevulinate synthase. Proc Natl Acad Sci USA 101 (2004) 9127-9132
33. Lip G.Y., McColl K.E., Goldberg A., and Moore M.R. Smoking and recurrent attacks of acute intermittent porphyria. BMJ 302 (1991) 507
34. Handschin C., Lin J., Rhee J., et al. Nutritional regulation of hepatic heme biosynthesis and porphyria through PGC-1alpha. Cell 122 (2005) 505-515
35. Degenhardt T., Vaisanen S., Rakhshandehroo M., Kersten S., and Carlberg C. Peroxisome proliferator-activated receptor alpha controls hepatic heme biosynthesis through ALAS1. J Mol Biol 388 (2009) 225-238
36. Delaby C., To-Figueras J., Deybach J.C., Casamitjana R., and Puy H. Herrero C. Role of two nutritional hepatic markers (insulin-like growth factor 1 and transthyretin) in the clinical assessment and follow-up of AIP patients. J Intern Med 266 (2009) 277-285
37. Kauppinen R., and Mustajoki P. Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases. Medicine (Baltimore) 71 (1992) 1-13
38. Bonkovsky H.L., Healey J.F., Lourie A.N., and Gerron G.G. Intravenous heme-albumin in acute intermittent porphyria: evidence for repletion of hepatic hemoproteins and regulatory heme pools. Am J Gastroenterol 86 (1991) 1050-1056
39. Anderson K.E., Bloomer J.R., Bonkovsky H.L., et al. Recommendations for the diagnosis and treatment of the acute porphyrias. Ann Intern Med 142 (2005) 439-450
40. Mustajoki P., Tenhunen R., Pierach C., and Volin L. Heme in the treatment of porphyrias and hematological disorders. Semin Hematol 26 (1989) 1-9
41. Siegert S.W., and Holt R.J. Physicochemical properties, pharmacokinetics, and pharmacodynamics of intravenous hematin: a literature review. Adv Ther 25 (2008) 842-857
42. Anderson K.E., Bonkovsky H.L., Bloomer J.R., and Shedlofsky S.I. Reconstitution of hematin for intravenous infusion. Ann Intern Med 144 (2006) 537-538
43. Badminton M.N., and Deybach J.C. Treatment of an acute attack of porphyria during pregnancy. Eur J Neurol 13 (2006) 668-669
44. Pischik E., and Kauppinen R. Can pregnancy stop cyclical attacks of porphyria?. Am J Med 119 (2006) 88-90
45. Seth A.K., Badminton M.N., Mirza D., Russell S., and Elias E. Liver transplantation for porphyria: who, when, and how?. Liver Transpl 13 (2007) 1219-1227
46. Doss M.O., Kuhnel A., and Gross U. Alcohol and porphyrin metabolism. Alcohol Alcohol 35 (2000) 109-125
47. Thunell S., Pomp E., and Brun A. Guide to drug porphyrogenicity prediction and drug prescription in the acute porphyrias. Br J Clin Pharmacol 64 (2007) 668-679
48. Andersson C., and Lithner F. Hypertension and renal disease in patients with acute intermittent porphyria. J Intern Med 236 (1994) 169-175
49. Kauppinen R., and Mustajoki P. Acute hepatic porphyria and hepatocellular carcinoma. Br J Cancer 57 (1988) 117-120
50. Andant C., Puy H., Bogard C., et al. Hepatocellular carcinoma in patients with acute hepatic porphyria: frequency of occurrence and related factors. J Hepatol 32 (2000) 933-939
51. Andant C., Puy H., Faivre J., and Deybach J.C. Acute hepatic porphyrias and primary liver cancer. N Engl J Med 338 (1998) 1853-1854
52. Andersson C., Bjersing L., and Lithner F. The epidemiology of hepatocellular carcinoma inpatients with acute intermittent porphyria. J Intern Med 240 (1996) 195-201
53. Laiwah A.A., Mactier R., McColl K.E., Moore M.R., and Goldberg A. Early-onset chronic renalfailure as a complication of acute intermittent porphyria. Q J Med 52 (1983) 92-98
54. Murphy G.M. The cutaneous porphyrias: a review. The British Photodermatology Group. Br J Dermatol 140 (1999) 573-581
55. Altiparmak U.E., Oflu Y., Kocaoglu F.A., Katircioglu Y.A., and Duman S. Ocular complications in 2 cases with porphyria. Cornea 27 (2008) 1093-1096
56. Poh-Fitzpatrick M.B. Molecular and cellular mechanisms of porphyrin photosensitization. Photodermatol 3 (1986) 148-157
57. Timonen K., Niemi K.M., and Mustajoki P. Skin morphology in porphyria cutanea tarda does not improve despite clinical remission. Clin Exp Dermatol 16 (1991) 355-358
58. Timonen K., Niemi K.M., Mustajoki P., and Tenhunen R. Skin changes in variegate porphyria. Clinical, histopathological, and ultrastructural study. Arch Dermatol Res 282 (1990) 108-114
59. Maynard B., and Peters M.S. Histologic and immunofluorescence study of cutaneous porphyrias. J Cutan Pathol 19 (1992) 40-47
60. Hindmarsh J.T., Oliveras L., and Greenway D.C. Plasma porphyrins in the porphyrias. Clin Chem 45 (1999) 1070-1076
61. Elder G.H. Porphyria cutanea tarda. Semin Liver Dis 18 (1998) 67-75
62. Elder G.H. Identification of a group of tetracarboxylate porphyrins, containing one acetate and three propionate-substituents, in faeces from patients with symptomatic cutaneous hepatic porphyria and from rats with porphyria due to hexachlorobenzene. Biochem J 126 (1972) 877-891
63. de Verneuil H., Nordmann Y., Phung N., et al. Familial and sporadic porphyria cutanea: two different diseases. Int J Biochem 9 (1978) 927-931
64. Elder G.H., Lee G.B., and Tovey J.A. Decreased activity of hepatic uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N Engl J Med 299 (1978) 274-278
65. Aarsand A.K., Boman H., and Sandberg S. Familial and sporadic porphyria cutanea tarda: characterization and diagnostic strategies. Clin Chem 55 (2009) 795-803
66. Badenas C., To-Figueras J., Phillips J.D., Warby C.A., Munoz C., and Herrero C. Identification and characterization of novel uroporphyrinogen decarboxylase gene mutations in a large series of porphyria cutanea tarda patients and relatives. Clin Genet 75 (2009) 346-353
67. Bulaj Z.J., Phillips J.D., Ajioka R.S., et al. Hemochromatosis genes and other factors contributing to the pathogenesis of porphyria cutanea tarda. Blood 95 (2000) 1565-1571
68. Gisbert J.P., Garcia-Buey L., Pajares J.M., and Moreno-Otero R. Prevalence of hepatitis C virus infection in porphyria cutanea tarda: systematic review and meta-analysis. J Hepatol 39 (2003) 620-627
69. Fargion S., Piperno A., Cappellini M.D., et al. Hepatitis C virus and porphyria cutanea tarda: evidence of a strong association. Hepatology 16 (1992) 1322-1326
70. Egger N.G., Goeger D.E., Payne D.A., Miskovsky E.P., Weinman S.A., and Anderson K.E. Porphyria cutanea tarda: multiplicity of risk factors including HFE mutations, hepatitis C, and inherited uroporphyrinogen decarboxylase deficiency. Dig Dis Sci 47 (2002) 419-426
71. Roberts A.G., Whatley S.D., Morgan R.R., Worwood M., and Elder G.H. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic porphyria cutanea tarda. Lancet 349 (1997) 321-323
72. Roberts A.G., Whatley S.D., Nicklin S., et al. The frequency of hemochromatosis-associated alleles is increased in British patients with sporadic porphyria cutanea tarda. Hepatology 25 (1997) 159-161
73. Ellervik C., Birgens H., Tybjaerg-Hansen A., and Nordestgaard B.G. Hemochromatosis genotypes and risk of 31 disease endpoints: meta-analyses including 66,000 cases and 226,000 controls. Hepatology 46 (2007) 1071-1080
74. Dabrowska E., Jablonska-Kaszewska I., Bielawski K.P., and Falkiewicz B. Influence of hepatitis C virus (HCV) infection on porphyrin and iron metabolism in porphyria cutanea tarda (PCT) patients. Med Sci Monit 7 suppl 1 (2001) 190-196
75. Cruz-Rojo J., Fontanellas A., Moran-Jimenez M.J., et al. Precipitating/aggravating factors of porphyria cutanea tarda in Spanish patients. Cell Mol Biol (Noisy-le-grand) 48 (2002) 845-852
76. Lamoril J., Andant C., Gouya L., et al. Hemochromatosis (HFE) and transferrin receptor-1 (TFRC1) genes in sporadic porphyria cutanea tarda (sPCT). Cell Mol Biol (Noisy-le-grand) 48 (2002) 33-41
77. Ajioka R.S., Phillips J.D., Weiss R.B., et al. Down-regulation of hepcidin in porphyria cutanea tarda. Blood 112 (2008) 4723-4728
78. Phillips J.D., Bergonia H.A., Reilly C.A., Franklin M.R., and Kushner J.P. A porphomethene inhibitor of uroporphyrinogen decarboxylase causes porphyria cutanea tarda. Proc Natl Acad Sci USA 104 (2007) 5079-5084
79. Siersema P.D., ten Kate F.J., Mulder P.G., and Wilson J.H. Hepatocellular carcinoma in porphyria cutanea tarda: frequency and factors related to its occurrence. Liver 12 (1992) 56-61
80. Gisbert J.P., Garcia-Buey L., Alonso A., et al. Hepatocellular carcinoma risk in patients with porphyria cutanea tarda. Eur J Gastroenterol Hepatol 16 (2004) 689-692
81. Shieh S., Cohen J.L., and Lim H.W. Management of porphyria cutanea tarda in the setting of chronic renal failure: a case report and review. J Am Acad Dermatol 42 (2000) 645-652
82. Cordova K.B., Oberg T.J., Malik M., and Robinson-Bostom L. Dermatologic conditions seen in end-stage renal disease. Semin Dial 22 (2009) 45-55
83. Poh-Fitzpatrick M.B. Porphyria, pseudoporphyria, pseudopseudoporphyria...?. Arch Dermatol 122 (1986) 403-404
84. Sarkany R.P. The management of porphyria cutanea tarda. Clin Exp Dermatol 26 (2001) 225-232
85. Lecha M., Herrero C., and Ozalla D. Diagnosis and treatment of the hepatic porphyrias. Dermatol Ther 16 (2003) 65-72
86. Egger N.G., Goeger D.E., and Anderson K.E. Effects of chloroquine in hematoporphyrin-treated animals. Chem Biol Interact 102 (1996) 69-78
87. Valls V., Ena J., and Enriquez-De-Salamanca R. Low-dose oral chloroquine in patients with porphyria cutanea tarda and low-moderate iron overload. J Dermatol Sci 7 (1994) 169-175
88. Ippen H. Treatment of porphyria cutanea tarda by phlebotomy. Semin Hematol 14 (1977) 253-259
89. Badminton M.N., and Elder G.H. Management of acute and cutaneous porphyrias. Int J Clin Pract 56 (2002) 272-278
90. Anderson K.E., Goeger D.E., Carson R.W., Lee S.M., and Stead R.B. Erythropoietin for the treatment of porphyria cutanea tarda in a patient on long-term hemodialysis. N Engl J Med 322 (1990) 315-317
91. Peces R., de Salamanca R.E., Fontanellas A., et al. Successful treatment of haemodialysis-related porphyria cutanea tarda with erythropoietin. Nephrol Dial Transplant 9 (1994) 433-435
92. Murphy G.M. Diagnosis and management of the erythropoietic porphyrias. Dermatol Ther 16 (2003) 57-64
93. Holme S.A., Whatley S.D., Roberts A.G., et al. Seasonal palmar keratoderma in erythropoietic protoporphyria indicates autosomal recessive inheritance. J Invest Dermatol 129 (2009) 599-605
94. Holme S.A., Worwood M., Anstey A.V., Elder G.H., and Badminton M.N. Erythropoiesis and iron metabolism in dominant erythropoietic protoporphyria. Blood 110 (2007) 4108-4110
95. Lyoumi S., Abitbol M., Andrieu V., et al. Increased plasma transferrin, altered body iron distribution, and microcytic hypochromic anemia in ferrochelatase-deficient mice. Blood 109 (2007) 811-818
96. Delaby C., Lyoumi S., Ducamp S., et al. Excessive erythrocyte ppix influences the hematologic status and iron metabolism in patients with dominant erythropoietic protoporphyria. Cell Mol Biol (Noisy-le-grand) 55 (2009) 45-52
97. Schneider-Yin X., Gouya L., Meier-Weinand A., Deybach J.C., and Minder E.I. New insights into the pathogenesis of erythropoietic protoporphyria and their impact on patient care. Eur J Pediatr 159 (2000) 719-725
98. Doss M.O., and Frank M. Hepatobiliary implications and complications in protoporphyria, a 20-year study. Clin Biochem 22 (1989) 223-229
99. Rufenacht U.B., Gouya L., Schneider-Yin X., et al. Systematic analysis of molecular defects in the ferrochelatase gene from patients with erythropoietic protoporphyria. Am J Hum Genet 62 (1998) 1341-1352
100. Gouya L., Martin-Schmitt C., Robreau A.M., et al. Contribution of a common single-nucleotide polymorphism to the genetic predisposition for erythropoietic protoporphyria. Am J Hum Genet 78 (2006) 2-14
101. Gouya L., Puy H., Robreau A.M., et al. The penetrance of dominant erythropoietic protoporphyria is modulated by expression of wildtype FECH. Nat Genet 30 (2002) 27-28
102. Gouya L., Puy H., Lamoril J., et al. Inheritance in erythropoietic protoporphyria: a common wild-type ferrochelatase allelic variant with low expression accounts for clinical manifestation. Blood 93 (1999) 2105-2110
103. Gouya L., Deybach J.C., Lamoril J., et al. Modulation of the phenotype in dominant erythropoietic protoporphyria by a low expression of the normal ferrochelatase allele. Am J Hum Genet 58 (1996) 292-299
104. Whatley S.D., Mason N.G., Khan M., et al. Autosomal recessive erythropoietic protoporphyria in the United Kingdom: prevalence and relationship to liver disease. J Med Genet 41 (2004) e105
105. Sarkany R.P., Ross G., and Willis F. Acquired erythropoietic protoporphyria as a result of myelodysplasia causing loss of chromosome 18. Br J Dermatol 155 (2006) 464-466
106. Goodwin R.G., Kell W.J., Laidler P., et al. Photosensitivity and acute liver injury in myeloproliferative disorder secondary to late-onset protoporphyria caused by deletion of a ferrochelatase gene in hematopoietic cells. Blood 107 (2006) 60-62
107. Cox T.M. Erythropoietic protoporphyria. J Inherit Metab Dis 20 (1997) 258-269
108. Minder E.I., Schneider-Yin X., Steurer J., and Bachmann L.M. A systematic review of treatment options for dermal photosensitivity in erythropoietic protoporphyria. Cell Mol Biol 55 (2009) 84-97
109. Harms J., Lautenschlager S., Minder C.E., and Minder E.I. An alpha-melanocyte-stimulating hormone analogue in erythropoietic protoporphyria. N Engl J Med 360 (2009) 306-307
110. Anstey A.V., and Hift R.J. Liver disease in erythropoietic protoporphyria: insights and implications for management. Postgrad Med J 83 (2007) 739-748
111. McGuire B.M., Bonkovsky H.L., Carithers Jr. R.L., et al. Liver transplantation for erythropoietic protoporphyria liver disease. Liver Transpl 11 (2005) 1590-1596
112. Wahlin S., Srikanthan N., Hamre B., Harper P., and Brun A. Protection from phototoxic injury during surgery and endoscopy in erythropoietic protoporphyria. Liver Transpl 14 (2008) 1340-1346
113. Rand E.B., Bunin N., Cochran W., Ruchelli E., Olthoff K.M., and Bloomer J.R. Sequential liver and bone marrow transplantation for treatment of erythropoietic protoporphyria. Pediatrics 118 (2006) e1896-e1899
114. Whatley S.D., Ducamp S., Gouya L., et al. C-terminal deletions in the ALAS2 gene lead to gain of function and cause X-linked dominant protoporphyria without anemia or iron overload. Am J Hum Genet 83 (2008) 408-414
115. Fritsch C., Bolsen K., Ruzicka T., and Goerz G. Congenital erythropoietic porphyria. J Am Acad Dermatol 36 (1997) 594-610
116. Fontanellas A., Bensidhoum M., de Salamanca R.E., Tirado A.M., de Verneuil H., and Ged C. A systematic analysis of the mutations of the uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur J Hum Genet 4 (1996) 274-282
117. Desnick R.J., Glass I.A., Xu W., Solis C., and Astrin K.H. Molecular genetics of congenital erythropoietic porphyria. Semin Liver Dis 18 (1998) 77-84
118. Ged C., Moreau-Gaudry F., Richard E., Robert-Richard E., and de Verneuil H. Congenital erythropoietic porphyria: mutation update and correlations between genotype and phenotype. Cell Mol Biol (Noisy-le-grand) 55 (2009) 53-60
119. Phillips J.D., Steensma D.P., Pulsipher M.A., Spangrude G.J., and Kushner J.P. Congenital erythropoietic porphyria due to a mutation in GATA1: the first trans-acting mutation causative for a human porphyria. Blood 109 (2007) 2618-2621
120. Kontos A.P., Ozog D., Bichakjian C., and Lim H.W. Congenital erythropoietic porphyria associated with myelodysplasia presenting in a 72-year6old man: report of a case and review of the literature. Br J Dermatol 48 (2003) 160-164
121. Harada F.A., Shwayder T.A., Desnick R.J., and Lim H.W. Treatment of severe congenital erythropoietic porphyria by bone marrow transplantation. J Am Acad Dermatol 45 (2001) 279-282
122. Shaw P.H., Mancini A.J., McConnell J.P., Brown D., and Kletzel M. Treatment of congenital erythropoietic porphyria in children by allogeneic stem cell transplantation: a case report and review of the literature. Bone Marrow Transplant 27 (2001) 101-105
123. Fritsch C., Lang K., Bolsen K., Lehmann P., and Ruzicka T. Congenital erythropoietic porphyria. Skin Pharmacol Appl Skin Physiol 11 (1998) 347-357
124. Robert-Richard E., Moreau-Gaudry F., Lalanne M., et al. Effective gene therapy of mice with congenital erythropoietic porphyria is facilitated by a survival advantage of corrected erythroid cells. Am J Hum Genet 82 (2008) 113-124
125. Elder G.H., and Roberts A.G. Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 27 (1995) 207-214
126. Hessels J., Voortman G., van der Wagen A., van der Elzen C., Scheffer H., and Zuijderhoudt F.M. Homozygous acute intermittent porphyria in a 7-year6old boy with massive excretionsof porphyrins and porphyrin precursors. J Inherit Metab Dis 27 (2004) 19-27
127. Llewellyn D.H., Smyth S.J., Elder G.H., Hutchesson A.C., Rattenbury J.M., and Smith M.F. Homozygous acute intermittent porphyria: compound heterozygosity for adjacent base transitions in the same codon of the porphobilinogen deaminase gene. Hum Genet 89 (1992) 97-98
128. Frank J., McGrath J., Lam H., Graham R.M., Hawk J.L., and Christiano A.M. Homozygous variegate porphyria: identification of mutations on both alleles of the protoporphyrinogen oxidase gene in a severely affected proband. J Invest Dermatol 110 (1998) 452-455
129. Roberts A.G., Puy H., Dailey T.A., et al. Molecular characterization of homozygous variegate porphyria. Hum Mol Genet 7 (1998) 1921-1925
130. Kauppinen R., Timonen K., von und zu Fraunberg M., et al. Homozygous variegate porphyria: 20 y follow-up and characterization of molecular defect. J Invest Dermatol 116 (2001) 610-613
131. Martasek P., Nordmann Y., and Grandchamp B. Homozygous hereditary coproporphyria caused by an arginine to tryptophane substitution in coproporphyrinogen oxidase and common intragenic polymorphisms. Hum Mol Genet 3 (1994) 477-480
132. Schmitt C., Gouya L., Malonova E., et al. Mutations in human CPO gene predict clinical expression of either hepatic hereditary coproporphyria or erythropoietic harderoporphyria. Hum Mol Genet 14 (2005) 3089-3098
133. Lamoril J., Puy H., Gouya L., et al. Neonatal hemolytic anemia due to inherited harderoporphyria: clinical characteristics and molecular basis. Blood 91 (1998) 1453-1457
134. Jaffe E.K., and Stith L. ALAD porphyria is a conformational disease. Am J Hum Genet 80 (2007) 329-337
135. Gross U., Sassa S., Jacob K., et al. 5-Aminolevulinic acid dehydratase deficiency porphyria: a twenty-year clinical and biochemical follow-up. Clin Chem 44 (1998) 1892-1896
136. Doss M.O., Stauch T., Gross U., et al. The third case of Doss porphyria (delta-amino-levulinic acid dehydratase deficiency) in Germany. J Inherit Metab Dis 27 (2004) 529-536
137. Sassa S., and Kappas A. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone. J Clin Invest 71 (1983) 625-634
138. Zuazo E., Garaizar C., Labayru M., and Prats J.M. Neurological crisis in type 1 hereditary thyrosinemia. Neurologia 9 (1994) 296-299
139. Thunell S., Henrichson A., Floderus Y., et al. Liver transplantation in a boy with acute porphyria due to aminolaevulinate dehydratase deficiency. Eur J Clin Chem Clin Biochem 30 (1992) 599-606
140. Deybach J.C., Badminton M., Puy H., et al. European porphyria initiative (EPI): a platform to develop a common approach to the management of porphyrias and to promote research in the field. Physiol Res 55 suppl 2 (2006) 67-73